Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.77 Insider Own5.93% Shs Outstand95.93M Perf Week3.39%
Market Cap64.34M Forward P/E- EPS next Y-1.16 Insider Trans12.35% Shs Float95.88M Perf Month-51.06%
Income-290.25M PEG- EPS next Q-0.49 Inst Own98.03% Short Float / Ratio8.51% / 2.07 Perf Quarter-59.79%
Sales4.54M P/S14.17 EPS this Y-11.24% Inst Trans-0.22% Short Interest8.16M Perf Half Y-61.51%
Book/sh-0.50 P/B- EPS next Y53.31% ROA-104.20% Target Price9.46 Perf Year-86.74%
Cash/sh1.01 P/C0.63 EPS next 5Y- ROE-425.97% 52W Range0.20 - 5.64 Perf YTD-80.75%
Dividend- P/FCF- EPS past 5Y10.97% ROI- 52W High-88.81% Beta0.70
Dividend %- Quick Ratio1.42 Sales past 5Y42.51% Gross Margin-390.18% 52W Low217.88% ATR0.13
Employees334 Current Ratio1.50 Sales Q/Q-52.05% Oper. Margin-6417.09% RSI (14)41.58 Volatility15.86% 24.17%
OptionableYes Debt/Eq- EPS Q/Q20.10% Profit Margin-6390.31% Rel Volume0.37 Prev Close0.70
ShortableYes LT Debt/Eq- EarningsNov 01 BMO Payout- Avg Volume3.94M Price0.63
Recom2.71 SMA200.73% SMA50-43.33% SMA200-68.54% Volume1,456,351 Change-9.85%
Date Action Analyst Rating Change Price Target Change
Nov-09-23Downgrade Mizuho Buy → Neutral $31 → $1
Nov-09-23Downgrade H.C. Wainwright Buy → Neutral
Nov-09-23Downgrade Evercore ISI Outperform → In-line
Jul-20-22Downgrade Citigroup Neutral → Sell $8 → $3
Jul-13-22Downgrade Stifel Buy → Hold $16 → $5
Jul-13-22Downgrade JP Morgan Overweight → Neutral $10
May-10-22Downgrade Citigroup Buy → Neutral $15 → $8
May-13-21Upgrade JP Morgan Neutral → Overweight $23 → $29
Dec-09-20Downgrade Citigroup Buy → Neutral $20 → $27
Dec-08-20Reiterated H.C. Wainwright Buy $28 → $31
Dec-01-23 04:01PM
Nov-29-23 06:05PM
Nov-24-23 12:29PM
Nov-22-23 04:01PM
04:01PM Loading…
Nov-10-23 04:01PM
Nov-09-23 08:23AM
Nov-08-23 05:35PM
Nov-05-23 12:50PM
Nov-02-23 05:42AM
Nov-01-23 08:35AM
Oct-06-23 04:01PM
09:19AM Loading…
Sep-21-23 09:19AM
Sep-19-23 04:01PM
Sep-01-23 04:01PM
Aug-31-23 04:01PM
Aug-13-23 10:44AM
Aug-08-23 05:30PM
Aug-04-23 04:01PM
Aug-01-23 04:01PM
Jul-31-23 04:01PM
Jul-29-23 11:07AM
Jul-17-23 07:29AM
Jul-07-23 04:01PM
Jun-16-23 06:05AM
04:01PM Loading…
Jun-07-23 04:01PM
Jun-05-23 09:00AM
Jun-02-23 04:01PM
May-18-23 07:09AM
May-08-23 05:15PM
May-07-23 08:59AM
May-05-23 04:01PM
May-01-23 04:01PM
Apr-16-23 12:08PM
Mar-31-23 04:01PM
Mar-24-23 09:35AM
Mar-03-23 04:01PM
Mar-01-23 04:01PM
Feb-21-23 04:01PM
Feb-15-23 06:58AM
Feb-08-23 05:15PM
Feb-06-23 08:00AM
Feb-03-23 04:01PM
Jan-13-23 04:01PM
Jan-04-23 04:01PM
Dec-24-22 10:07AM
Dec-20-22 04:33PM
Dec-19-22 08:00AM
Dec-15-22 04:01PM
Dec-12-22 10:00AM
Dec-02-22 04:01PM
Nov-23-22 08:00AM
Nov-22-22 05:03AM
Nov-10-22 05:52AM
Nov-09-22 04:01PM
Nov-08-22 05:15PM
Nov-04-22 04:01PM
Nov-01-22 04:05PM
Oct-26-22 02:01AM
Oct-14-22 07:08AM
Oct-13-22 12:51PM
Oct-10-22 04:01PM
Oct-07-22 10:01AM
Oct-06-22 01:36PM
Sep-30-22 08:59AM
Sep-29-22 11:09AM
Sep-28-22 04:01PM
Sep-27-22 10:13AM
Sep-21-22 06:32PM
Sep-13-22 03:45PM
Sep-07-22 01:31PM
Sep-06-22 09:26AM
Sep-05-22 10:21AM
Aug-31-22 04:01PM
Aug-25-22 11:52AM
Aug-24-22 06:03PM
Aug-23-22 01:53PM
Aug-16-22 10:09AM
Aug-15-22 09:55AM
Aug-11-22 01:13PM
Aug-09-22 03:01PM
Aug-08-22 05:35PM
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Touchon PascalPresident and CEONov 16Sale0.3920,4097,939655,496Nov 20 05:31 PM
Joshi ManherEVP, Chief Medical OfficerNov 16Sale0.3912,2874,780171,284Nov 20 05:30 PM
Hyllengren Eric JSVP, CFONov 16Sale0.3911,9584,652205,998Nov 20 05:29 PM
Nguyen AnhCoEVP, Chief Sci. & Tech OfficerNov 16Sale0.398,8563,445277,143Nov 20 05:31 PM
Murugan AmarEVP, Chief Legal OfficerNov 16Sale0.398,3073,231257,084Nov 20 05:30 PM
Henrich JillEVP, Global Head RA & QualityNov 16Sale0.393,2671,271104,424Nov 20 05:29 PM
Gallagher Carol GiltnerDirectorNov 14Buy0.3190,98028,186459,418Nov 15 05:07 PM
Gallagher Carol GiltnerDirectorNov 13Buy0.22179,02040,029368,438Nov 15 05:07 PM
DOBMEIER ERICDirectorNov 10Buy0.23446,825101,340563,325Nov 14 06:27 PM
HEIDEN WILLIAM KDirectorNov 10Buy0.25100,00025,330209,000Nov 14 06:29 PM
Touchon PascalPresident and CEOAug 16Sale1.6530,76650,835675,905Aug 18 06:25 PM
Nguyen AnhCoEVP, Chief Sci. & Tech OfficerAug 16Sale1.6515,12624,997285,999Aug 18 06:25 PM
Murugan AmarEVP, Chief Legal OfficerAug 16Sale1.658,67214,330265,391Aug 18 06:25 PM
Hyllengren Eric JSVP, CFOAug 16Sale1.658,18613,527217,956Aug 18 06:25 PM
Joshi ManherEVP, Chief Medical OfficerAug 16Sale1.656,97511,526183,571Aug 18 06:25 PM
Henrich JillEVP, Global Head RA & QualityAug 16Sale1.653,3465,531107,691Aug 18 06:25 PM
Touchon PascalPresident and CEOJun 27Sale1.6614,29123,723706,671Jun 29 04:15 PM
Touchon PascalPresident and CEOMay 16Sale2.0429,76660,633720,962May 18 08:17 PM
Banard Charlene A.EVP, Chief Technical OfficerMay 16Sale2.0419,04038,784276,010May 18 08:17 PM
Murugan AmarEVP, Chief Legal OfficerMay 16Sale2.048,38917,089270,945May 18 08:17 PM
Hyllengren Eric JSVP, CFOMay 16Sale2.047,91816,131226,142May 18 08:17 PM
Touchon PascalPresident and CEOMar 02Sale3.6315,67956,868750,728Mar 06 06:49 PM
Koppikar UtpalChief Financial OfficerMar 02Sale3.636,87124,921181,978Mar 06 06:47 PM
Dupont JakobEVP, Head of R&DMar 02Sale3.635,07418,403290,794Mar 06 06:46 PM
Murugan AmarSVP, GC & SecretaryMar 02Sale3.634,22115,310279,334Mar 06 06:48 PM
Koppikar UtpalChief Financial OfficerFeb 07Sale5.462,48513,568188,849Feb 09 05:00 PM